A Multicentre Trial with Pindolol

SUMMARYTheefficacy and safety of 15 mg tablets of pindolol were investigated in a field trial in which 7,062 hypertensive patients participated under conditions of general practice. 51070 of the patients had been under treatment with conventional antihypertensive drugs (com binations of rauwolfia alkaloids with diuretics, methyldopa, etc.) immediately prior to com mencement of therapy with pindolol. 92% of the patients started treatment with 15 mg pindolol (one tablet) daily, this dosage being maintained throughout the trial in 79% of the patients. Treatment was given for an average of six weeks and mean blood pressure fell during this time from 180/100 mm Hg to 153/88 mm Hg. Individual falls varied as a function of initial pressure but, with increasing age, the relative reductions in blood pressure (ie relative to starting values) diminished. However, in qualitative terms, 79070 of all patients responded positively. No problems were en countered as a

[1]  F. Gyntelberg,et al.  Antihypertensive treatment with pindolol in one or two doses. A comparative trial. , 2009, Acta medica Scandinavica.

[2]  J. Koch-weser.  Arterial hypertension in old age. , 1978, Herz.

[3]  C. Kaye,et al.  Studies of cardioselectivity and partial agonist activity in beta-adrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise. , 1978, British journal of clinical pharmacology.

[4]  G. Frithz.  Once a day treatment of hypertension. , 2009, Acta medica Scandinavica. Supplementum.

[5]  R. Pedrinelli,et al.  The effect of beta‐adrenergic blockade on patterns of urinary sodium excretion, blood pressure and plasma renin activity in patients with essential and renovascular hypertension , 1977, European journal of clinical investigation.

[6]  F. Gross.  Beta‐adrenergic blockade, blood pressure, and the renin‐angiotensin system , 1977, European journal of clinical investigation.

[7]  A. Marshall,et al.  Beta blockade in essential hypertension: an analysis of response to oxprenolol. , 1977, British heart journal.

[8]  A. Marshall,et al.  Treating hypertension. The place of beta blockade. , 1977, British heart journal.

[9]  H. Brunner.  The antihypertensive effect of beta-blockers. , 1977, Contributions to Nephrology.

[10]  J. E. Murphy.  General Practice Experience with Pindolol: A Multi- centre Study , 1977 .

[11]  A. Zanchetti,et al.  Regulation of renin secretion. , 1977, Contributions to Nephrology.

[12]  L. Wilhelmsen,et al.  Sodium excretion and sympathetic activity in relation to severity of hypertension. , 1977, Contributions to Nephrology.

[13]  L. Hansson,et al.  Long-term Hypotensive Effect of Atenolol (ICI 66.082), a New β-adrenergic Blocking Agent , 2009 .

[14]  W. Ulmer,et al.  [Propranolol and pindolol in chronic obstructive lung disease (author's transl)]. , 1976, Deutsche medizinische Wochenschrift.

[15]  K. Kelly.  Beta blockers in hypertension: a review. , 1976, American journal of hospital pharmacy.

[16]  L. Beilin,et al.  Renin unresponsiveness and the effects of oxprenolol, methyldopa and spironolactone in patients with essential hypertension. , 1976, Australian and New Zealand journal of medicine.

[17]  F. Skrabal,et al.  Immediate plasma renin response to propranolol: differentiation between essential and renal hypertension. , 1976, British medical journal.

[18]  J. Kopecká,et al.  Relationship between plasma renin activity and urinary catecholamines in various types of hypertension. , 1976, Endokrinologie.

[19]  A. Marshall,et al.  COMPARISON OF OXPRENOLOL AND METHYLDOPA IN HYPERTENSION A Within-patient Double-blind Trial , 1976, The Lancet.

[20]  A. Blowers,et al.  The use of pindolol in the treatment of essential hypertension: a multi-centre assessment. , 1976, Current medical research and opinion.

[21]  P. Boer,et al.  Change in the renin dependency of blood pressure induced by volume depletion and/or propranolol therapy in hypertensive patients. , 1976, Clinical science and molecular medicine. Supplement.

[22]  W. Louis,et al.  A comparison of beta adrenergic blocking drugs in the treatment of hypertension , 1974 .

[23]  C. Wilhelmsson,et al.  Comparative study of alprenolol and methyldopa in previously untreated essential hypertension. , 1973, British heart journal.

[24]  D. Greenblatt,et al.  Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. , 1973, American heart journal.

[25]  P. Coller.  Clinical Experience with Visken, (Prindolol) in Essential Hypertension: Its Special Comparative Action to Aldomet (Methyldopa) , 1973 .

[26]  J. Vickers,et al.  Propranolol in hypertension: a study of long-term therapy, 1964-1970. , 1972, American heart journal.

[27]  P. Gillam,et al.  Treatment of Hypertension with Propranolol , 1969, British medical journal.

[28]  S. Stephen.  Unwanted effects of propranolol. , 1966, The American journal of cardiology.